Skip to main content
SpringerLink
Log in

Alnylam launches era of RNAi drugs

  • News
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

  • 06 September 2018

    In the version of this article initially published, the company's name was given as Alnylam Therapeutics instead of Alnylam Pharmaceuticals in the first sentence and as Alynlam instead of Alnylam in the image caption. The error has been corrected in the HTML and PDF versions of the article.

Author information

Authors and Affiliations

  1. Ann Arbor, Michigan

    Ken Garber

Authors
  1. Ken Garber
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garber, K. Alnylam launches era of RNAi drugs. Nat Biotechnol 36, 777–778 (2018). https://doi.org/10.1038/nbt0918-777

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0918-777

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation